B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PPARD

MOLECULAR TARGET

peroxisome proliferator activated receptor delta

UniProt: BAH02282NCBI Gene: 546736 compounds

PPARD (peroxisome proliferator activated receptor delta) is targeted by 36 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PPARD

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Bezafibrate1.614
2Dactinomycin1.614
3Ethidium1.614
4cycloheximide1.393
5Clotrimazole1.102
6Hexachlorophene1.102
7Sodium Dodecyl Sulfate1.102
8Apigenin 5,7,4'-trihydroxy-flavone,0.691
9Arachidonic Acid0.691
10Genistein0.691
11Oleic Acid0.691
12Mepentol [Supplementary Concept]0.691
13Aprepitant0.691
14Astemizole Antihistamine drug now withdrawn from0.691
15Bisphenol A-Glycidyl Methacrylate0.691
16Bortezomib0.691
17Chlorhexidine0.691
18Dasatinib0.691
19Daunorubicin0.691
20Disulfiram0.691
21Ethinyl Estradiol0.691
22Fenofibrate0.691
23Fluspirilene0.691
24gamma-Linolenic Acid0.691
25Idazoxan0.691
26Linoleic Acid0.691
27Loratadine0.691
28Vitamin K 30.691
29Myristic Acid0.691
30Palmitic Acid0.691
31Promethazine0.691
32Prostaglandin D20.691
33Retinaldehyde0.691
34Rotenone0.691
35Spironolactone0.691
36Sulbactam0.691

About PPARD as a Drug Target

PPARD (peroxisome proliferator activated receptor delta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 36 compounds with documented PPARD interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PPARD inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.